Ijeoma Ezeife, MD
Cardiovascular Disease · Newark, DENPI 1851730048
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Heartflow, Inc. at 28.1% of the total. That places this record below the midpoint for cardiovascular disease clinicians in DE, where the typical reported total is $2,459.
Across 72 payments — averaging $28.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$566
- Johnson & Johnson$286
- Novartis$276
- Pfizer$223
- Abiomed$134
- Abbott$114
- plus $420 from 10 others
What the payments were for
- Food & beverage$2,018100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 7 | $566 |
| Johnson & Johnson | 15 | $286 |
| Novartis | 19 | $276 |
| Pfizer | 6 | $223 |
| Abiomed | 2 | $134 |
| Abbott | 1 | $114 |
| E.r. Squibb & Sons, L.L.C. | 4 | $63 |
| AstraZeneca | 4 | $61 |
| Kestra Medical Technology Services, Inc. | 3 | $60 |
| Daxor Corporation | 1 | $59 |
| Amgen | 3 | $50 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $34 |
| Philips North America LLC | 1 | $30 |
| Boehringer Ingelheim | 2 | $30 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$500
- VYNDAQEL$123
- XARELTO$120
- Mitra Clip system$114
How this compares
$2,018 in reported general payments places this provider in the 45th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 147 | $149,095 |
| XareltoRivaroxaban | 41 | $49,681 |
| EntrestoSacubitril/Valsartan | 31 | $48,179 |
| JardianceEmpagliflozin | 23 | $25,215 |
| Repatha SureclickEvolocumab | 15 | $8,318 |
| FarxigaDapagliflozin Propanediol | 11 | $7,383 |
| Metoprolol Succinate | 162 | $1,998 |
| Rosuvastatin Calcium | 95 | $1,449 |
| Atorvastatin Calcium | 126 | $1,339 |
| Ranolazine ErRanolazine | 11 | $952 |
| Amlodipine Besylate | 111 | $554 |
| Carvedilol | 91 | $501 |
| Pravastatin Sodium | 20 | $497 |
| Losartan Potassium | 42 | $373 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 15 | $322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $223 | $149,095147 claims |
| Johnson & JohnsonXarelto | $286 | $49,68141 claims |
| NovartisEntresto | $276 | $48,17931 claims |
| Boehringer IngelheimJardiance | $30 | $25,21523 claims |
| AstraZenecaFarxiga | $61 | $7,38311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Newark
- Edward GoldenbergNewark$52K
- Muhammad ShakirNewark$47K
- Anthony AlfieriNewark$45K
- Sean DikdanNewark$42K
- Kirk GarrattNewark$38K
- Anthony ClayNewark$37K
- Ashish ParikhNewark$26K
- William WeintraubNewark$24K
- Wen Chi TsaiNewark$20K
- Stephen MengNewark$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.